Monday, September 8, 2008

Proteolix Takes $79M In Third Round

South San Francisco-based Proteolix said Monday that it has raised $79M in a Series C funding round. The firm, which is developing novel therapeutics for the treatment of cancer and autoimmune diseases, said the round was led by Nomura Phase4 Ventures. The round also included new investor Westfield Capital Management. Existing investors, Advanced Technology Ventures, Delphi Ventures, Latterell Venture Partners, U.S. Venture Partners and The Vertical Group also participated. Proteolix said the funding will go towards Phase 2 clinical trials of its carfilzomib compound, Phase 3 trials for its anti-cancer therapeutic, and also towards other drugs in its earlier stage pipeline. More information »